CMEL20008, Victor, EA6174, Merkel Cell Carcinoma, Pembrolizumab
Basic Study Information
Purpose:Location: University of Rochester
This phase III trial studies how well pembrolizumab works compared to standard of
care observation in treating patients with stage I-III Merkel cell cancer that has
been completely removed by surgery (resected). Immunotherapy with monoclonal antibodies,
such as pembrolizumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread.
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search